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Diffuse mesangial sclerosis occurs as an isolated abnormality
or as a part of a syndrome. Recently, mutations in
phospholipase C epsilon 1 (PLCE1) were found to cause a
nonsyndromic, autosomal recessive form of this disease. Here
we describe three children from one consanguineous kindred
of Pakistani origin with diffuse mesangial sclerosis who
presented with congenital or infantile nephrotic syndrome.
Homozygous mutations in PLCE1 (also known as KIAA1516,
PLCE, or NPHS3) were identified following genome-wide
mapping of single-nucleotide polymorphisms. All affected
children were homozygous for a four-basepair deletion in
exon 3, which created a premature translational stop codon.
Analysis of the asymptomatic father of two of the children
revealed that he was also homozygous for the same
mutation. We conclude this nonpenetrance may be due to
compensatory mutations at a second locus and that mutation
within PLCE1 is not always sufficient to cause diffuse
mesangial sclerosis.
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Congenital nephrotic syndrome is defined as proteinuria
leading to clinical symptoms presenting in the first 3 months
after birth.1 This age cutoff is arbitrary and not an adequate
classification of early onset nephrotic syndrome. Genetically
determined congenital or infantile nephrotic syndrome is
classified into Finnish Type congenital nephrotic syndrome,
focal segmental glomerulosclerosis, and diffuse mesangial
sclerosis (DMS). Less frequently it may be caused by a
mitochondrial disorder.2 Finnish type congenital nephrotic
syndrome is caused by mutations in NPHS1, which codes for
the slit diaphragm protein nephrin.3 Autosomal recessive focal
segmental glomerulosclerosis is caused by mutations in NPHS2
which codes for podocin, but for it to present in the first 3
months of life (congenital focal segmental glomerulosclerosis)
there is evidence that it requires a ‘tri-allelic hit’ with mutations
of any three of the four alleles of NPHS1 and NPHS2.4 DMS
may occur as part of a syndrome or as an isolated abnormality.
Denys–Drash syndrome (nephropathy, Wilm’s tumor, and
genital abnormalities) is caused by mutations of WT15 whereas
Pierson syndrome (DMS with microcoria) is caused by
mutations of lamininb-2.6 The genetic basis for Galloway–
Mowat syndrome (DMS with neuronal migration disorder) is
unknown. Some patients with nonsyndromic DMS inherited as
an autosomal-dominant disease have mutations in WT1.7,8 In
2006, Hinkes et al.9 described mutations in phospholipase C
epsilon 1 (PLCE1) as a cause of nonsyndromic, autosomal
recessive DMS and in 2007 Gbadegesin et al.10 found PLCE1
mutations in 10 of 35 cases. The molecular mechanisms by
which these mutations cause DMS are unknown.
We undertook genetic studies in a consanguineous
kindred of Pakistani origin with three affected children to
determine the genetic cause of DMS in this family. The
pedigree structure (Figure 1) indicated that an autosomal
recessive pattern was the most likely mode of inheritance.
CASE REPORTS
The family tree is shown in Figure 1. The index patient was
individual 3. He presented at 14 months of age with
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nephrotic syndrome (periorbital edema, plasma albumin
concentration 9 g/l (normal 34–45), urine protein/creatinine
ratio 3904 mg/mmol (normal o23)) and renal impairment
(plasma creatinine 94 mmol/l, estimated glomerular filtration
rate 34 ml/min per 1.73 m2.) His blood pressure was
severely elevated at 140/80. The rest of the examination was
normal. A renal biopsy showed features of DMS with
extensive chronic tubulointerstitial nephritis (Figure 2a). A
computed tomography scan of his head showed no evidence
of structural abnormality. He received treatment with
prednisolone, ciclosporin, an ACE inhibitor (enalapril), a
calcium channel blocker (amlodipine), and a b-blocker
(atenolol). In spite of this he progressed rapidly to end-stage
renal failure and hemodialysis was commenced 1 month
after initial presentation. At 3 months after the initial
presentation he developed severe pancreatitis and died. His
post-mortem head circumference was 46 cm, on the 9th
centile for age.
Individual 19 is the cousin of the index patient. At 5
months of age his parents sought medical advice as they were
concerned that he might have the same renal condition.
Urinalysis showed 4þ proteinuria and he was referred to our
hospital for further assessment. Clinical examination showed
that his length (67 cm) and weight (7.8 kg) were on the 50th
centile for age but his head circumference (41 cm) was on the
0.4th. His blood pressure was 80 mm Hg systolic. The rest of
the examination was normal apart from a coronal hypospa-
dias. Investigations showed a plasma creatinine concentration
of 44 mmol/l (estimated glomerular filtration rate of 51 ml/
min per 1.73 m2), plasma albumin of 34 g/l and a urine
protein/creatinine ratio of 1002 mg/mmol. A renal biopsy
shortly after presentation confirmed the diagnosis of DMS
(Figure 2b) Further investigation confirmed the presence of
hemoglobin E, known to be present in the family. An MRI
scan of his head showed no abnormalities and an
ophthalmologic examination was normal. He has been
treated with ACE inhibitors, but no glucocorticosteroids or
other immunosuppressive drugs. His proteinuria has re-
sponded well to therapy. His urine protein/creatinine ratio
was 42 mg/mmol and his estimated glomerular filtration rate
99 ml/min per 1.73 m2 at age 61 months.
Individual 4 is the brother of the index patient. The
pediatric renal unit was alerted to the fact that his mother
was pregnant and he was first seen on the day after his birth.
Clinical examination was normal. The urinary protein/
creatinine ratio was 65 mg/mmol, rising to 154 mg/mmol
on day 4 after birth. At 1 week of age his blood pressure was
80 mm Hg systolic and the urine protein/creatinine ratio was
158 mg/mmol. He was started on captopril with a reduction
in protein/creatinine ratio to 68 mg/mmol. His urine protein/
creatinine ratio peaked at over 2000 mg/mmol but has
reduced to 307 mg/mmol at 33 months with an increased
dose of ACE inhibitor. His estimated glomerular filtration
rate is 108 ml/min per 1.73 m2. His weight and length have
grown along the 2nd centile and his head circumference
along the 0.4th. A renal biopsy at 1 year of age confirmed the
diagnosis of DMS with areas of chronic tubulointerstitial
damage (Figure 2c).
Individual 2 is the father of two of the affected children.
He was born in the United Kingdom after a pregnancy
apparently complicated by polyhydramnios. As a child he had
mild asthma but no other illnesses. He was on no regular
medication. His height is 168.8 cm and his head circumfer-
ence 56 cm, which is on the 25th centile of head
circumference for height.11 He is normotensive (BP 112/90)
and has normal renal function (plasma creatinine 79 mmol/l)
with no proteinuria (urine protein/creatinine ratio 5 mg/
mmol).
RESULTS
Single nucleotide polymorphism (SNP) array analysis of
three affected individuals revealed two long regions of
homozygosity. The most promising region common to the
three affected and none of the four unaffected individuals
tested, was a 3.0 Mb (42.6 LDU) region located at chromo-
some 10q23. This region contained the PLCE1 gene
implicated in other DMS cases.9 A 4 bp deletion,
c.1303_1306delAGGA; p.R434X, was identified in exon 3 of
the PLCE1 gene (reference sequence ensemble transcript ID
ENST00000371380). This mutation directly generates a
premature translational termination signal at codon 434
(Figure 3).
Unaffected individuals 1, 8, 62, 63, and 98 were found to
be heterozygous carriers of the mutation. Affected indivi-
duals 3, 4, and 19 were found to be homozygous for the
deletion.
Unaffected individual 2 was also found to be homozygous
for the deletion. Analysis with two alternative sets of PCR
primers also indicated homozygosity for the deletion in
individual 2 (data not shown) thus eliminating the possibility
of a PCR primer binding site mutation causing artefactual
amplification failure. Both parents of individual 2 were






























Figure 1 | Extract of the extended pedigree of the affected
kindred.
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dependent probe amplification (MLPA) analysis shows no
evidence of a normal exon 3 sequence in individual 2.
Methylation analysis of the INPP5a gene showed no
methylation anomaly indicating normal biparental inheri-
tance of chromosome 10. Repeat DNA samples from both
peripheral lymphocytes and saliva of individual 2 were
analyzed and found to be homozygous for the deletion in
both samples. No evidence of mosaicism for the normal
PLCE1 exon 3 sequence was seen (data not shown).
Analysis of CA repeat polymorphisms confirmed homo-
zygosity in the region of the PLCE1 gene. Individual 2 was
homozygous for CA repeats D10S2316, D10S1680, and
D10S520 at 96, 95.6, and 96.4 Mb, respectively, on chromo-
some 10. These markers are highly polymorphic and very
close to the PLCE1 locus at 95.8 Mb (ENSEMBL, release 50).
D10S2316 analysis was also performed on the three affected
men who were all homozygous for the same allele as
individual 2.
A total of 32 family members were analyzed for the PLCE1
c.1303_1306del AGGA mutation. No other unaffected
homozygotes were found.
DISCUSSION
We have described a consanguineous kindred in which three
children are affected by DMS. All three are homozygous for a
4 bp deletion in exon three of the PLCE1 gene. This deletion
results in a premature translational stop codon. This is
completely consistent with previous descriptions of muta-
tions of this gene as a cause of DMS. Both Hinkes et al.9 and
Gbadegesin et al.10 describe DMS patients with PLCE1
mutations generating premature translational termination
signals. The physiological substrates of PLCE1 are unknown
as are the mechanisms by which abnormalities of this protein
lead to this devastating renal disease.
The finding of an apparently pathogenic homozygous
mutation in a phenotypically completely normal adult
suggests that other factors significantly modify the effect of
abnormalities of PLCE1. This could include the possibility
that mutations at another locus render mutations of PLCE1
nonpathogenic. Possible candidates might include BRAF and
IQGAP1, both of which interact with PLCE1.12 Alternatively,
a pathogenic mutation in one or both alleles at a different
locus or an environmental challenge early in development
may be necessary in addition to PLCE1 mutations for a
clinical presentation with nephrotic syndrome. Less likely
explanations include the possibility that PLCE1 mutations are
not pathogenic and are an incidental finding in this family.
This was discounted as this gene is known to be implicated in
other families with DMS and was identified through
homozygosity mapping in the three affected individuals.
Figure 2 | Light microscopy of renal biopsies (silver stain). (a) Biopsy taken from individual 3 at 15 months of age. (b) Biopsy from
individual 19 at 5 months of age. (c) Biopsy from individual 4 taken at 12 months of age. All biopsies show prominence of the mesangial
matrix and podocytes with varying degrees of glomerular sclerosis and tubulointerstitial fibrosis. All were stained with Jones’ silver stain.
Original magnification  200.
4 bp deletion, c.1303-1306delAGGA, in exon 3 of the PLCE1 gene 
Figure 3 | DNA sequence analysis of exon 3 of the PLCE1 gene. (a) Sequencing data for bases 1293–1313 of exon 3 of the PLCE1 gene in a
normal individual. (b) Sequencing data of an affected member of the pedigree showing deletion of bases 1303–1306. (c) Interpretation of
sequence data indicating AGGA deletion (bold) and generation of the translational termination codon TAA (underlined).
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Mosaicism for uniparental disomy in the unaffected homo-
zygote causing reduction to homozygosity at 10q23 in the
blood but not in kidney tissue was also postulated but
excluded as far as possible by molecular investigation, which
detected no evidence of mosaicism. The possibility was
considered that the mutation may affect RNA splicing and
cause varying degrees of skipping of part of exon 3 in
different individuals and contribute to the nonpenetrance in
individual 2. However in silico analysis using the splice site




showed no evidence of this. Furthermore, the orthologous
murine PLCE1 sequence shows a high degree of conservation
of the exon 3 amino-acid sequence indicating that it is likely
to be important for PLCE1 function (data not shown).
Although the exact mechanism to explain the nonpene-
trance seen in the family is not known, variable expression is
another possibility given that there have been so few families
described and the natural history of the disorder is yet to be
fully characterized. It remains a possibility that subclinical
early disease followed by spontaneous remission would mean
that individuals investigated for the first time as adults are no
longer symptomatic. Interestingly a mouse model with
homozgous deletion of PLCE1 did not exhibit a nephrosis-
like phenotype.13
Hinkes et al.9 suggested that DMS caused by mutations of
PLCE1 might respond to treatment with steroids and/or
ciclosporin. We treated the index patient with these agents
with no beneficial effect. It is possible that he presented with
disease that was too far advanced to respond to any such
treatment. Indeed he progressed with extreme rapidity to
end-stage renal failure. We cannot exclude the possibility that
the nephrotoxicity of cyclosporin contributed to the rapid
deterioration of his renal function. In either event we would
recommend caution in using these agents on affected patients
in future. Our patients have responded well to ACE inhibitors
and we feel that these agents should be first-line treatment for
affected patients.
We have described here, for the first time, a healthy adult
individual with a homozygous truncating mutation of the
PLCE1 gene. We conclude that either changes in other genes
might be required to render mutations of PLCE1 deleterious,
or, more likely, that one or more mutations at other loci can
render an apparently pathogenic, truncating mutation of
PLCE1 benign. The discovery of more families with this DMS
may help to further our understanding.
MATERIALS AND METHODS
SNP array analysis
Five individuals were genotyped for SNPs on the Illumina
HumanHap 550K bead array; three affected (3, 4, and 19) and
two unaffected (individuals 25 and 114 in the extended pedigree).
The same three affected individuals and unaffected individuals 17,
18, and 25 were genotyped on the Affymetrix GeneChip 500K
Mapping Array Set. The genotype data were analyzed using
specifically designed software in the C programming language. This
recorded the locations of tracts of continuously homozygous SNPs
common to the affected individuals, with the same allele present at
each locus (that is the same underlying haplotype).
The regions detected in this analysis were prioritized by length
on the genetic scale using linkage disequilibrium units (LDU), from
LDU maps produced by the LDMAP program14 from genome-wide
HapMap data.15 This accounts for the association with LD structure
and prioritizes regions of autozygosity over tracts of homozygosity
associated with high LD.
PLCE1 sequence analysis
DNA was extracted from samples of peripheral blood (and saliva for
individual 2) using standard techniques.16 PCR amplification of
PLCE1 gene exons was performed before sequencing using the
primers described by Hinkes et al.9 Further sequencing of exon 3
was performed in individual 2 using the primers originally described
by Hinkes et al. (viz E3F: 50ttgcacttggagcatctgag and E3R:
50tgaacttaattttccatcaggag) as well as two alternate sets of primers
(E3alt1F: 50ggttaatgcatgagccgagt; E3alt1R: 50ttctcttaaagaagcgacttttactta
and E3alt2F: 50gtcatcttggcattttgtca; E3alt2F 50tccttctctgtagtcaaagatagaaa)
Reactions were in a 20 ml volume containing 50 ng DNA, 1 mM
forward primer, 1 mM reverse primer, 2 ml 10 reaction buffer
(Qiagen, Crawley, UK), 0.2 mM dNTPs, 2 mM MgCl2, 0.5 U Taq
polymerase (HotStar Taq; Qiagen). Cycling parameters were 94 1C
for 12 min followed by 32 cycles at 94 1C for 30 s, 55 1C for 30 s,
72 1C for 30 s. PCR products were sequenced bidirectionally using
the ABI Big Dye terminator v 1.1 cycle sequencing kit (Applied
Biosystems, Warrington, UK) and the same primers as for PCR
amplification. Results were analyzed with Mutation surveyor version
3.2 (Soft Genetics, State College, PA). Genotyping results for 12
individuals are shown in Figure 1. A further 20 individuals have
been genotyped. They were either homozygous for the normal allele
or heterozygous.
UPD analysis
Investigation for possible mosaic uniparental disomy of chromo-
some 10 in individual 2 was carried out by methylation analysis of
the imprinted INPP5a gene based on the method of Zeschnigk
et al.17 Genomic DNA (2mg) was bisulphite treated, followed by
methylation-sensitive PCR amplification (msPCR) and size analysis
using an ABI 3100 automated DNA analyzer. The methylated and
nonmethylated alleles generate PCR products of different length
thus enabling the resultant peak heights to be used as a measure of
the relative proportions of the alleles present in the sample. Peak
height ratios were compared with those of four normal control
samples (data not shown).
MLPA analysis
Dosage analysis was carried out using MLPA probes designed
specifically for normal sequence in exon 3, the probe binding site
comprising bases 1279–1326 of PLCE1 (reference sequence ensembl
transcript ID ENST00000371380, base 1 being the first base of the
ATG translation initiation codon). (Probe sequence: PLCE1_3L:
GGGTTCCCTAAGGGTTGGACCAGCCTCCGAGACAGCCCATGGA;
PLCE1_3R AGGATAAGCGTTGGTCCATGCTTACCTACCGTGTTC
TAGATTGGATCTTGCTGGCAC). The probes were diluted to
1.33 fmol/ml, and 1.5ml of this was used for MLPA in conjunction
with a commercially available MLPA probe mix (CFTR-P10, 91;
MRC-Holland, Amsterdam, the Netherlands) to provide controls.
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The standard protocol of MRC-Holland18 was used reducing the
initial DNA denaturation volume to 3.5 ml to allow for the extra
1.5ml of PLCE1 probe mix.
Microsatellite analysis
Microsatellite analysis was carried out by PCR amplification of DNA
using primers for polymorphic (CA)n repeat sequences in the region
of the PLCE1 gene. One primer from each pair was labeled with a
fluorophore. 50 ng of DNA was amplified using HotStarTaq
polymerase (Qiagen) under the conditions recommended by the
manufacturer with additional magnesium to a final concentration of
2 mM. PCR amplification conditions were as follows: 95 1C for
10 min followed by 32 cycles of 94 1C for 30 s; 55 1C for 30 s; 72 1C
for 30 s followed by 7 min at 72 1C. PCR products were run on an
ABI 3100 automated sequencer for separation, visualization and
sizing.
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